The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management highlighted the company's transformation from a single-product entity to a diversified commercial leader with three first-in-class medicines annualizing at approximately $4 billion in sales.

INGREZZA performance was driven by record new patient additions and sustained underlying demand, leading to a raised full-year guidance midpoint reflecting 13% year-over-year growth.

CRENESSITY's launch success is attributed to steady new patient starts and high persistence, with management noting that 15% of the diagnosed classic CAH population has already been prescribed the therapy.

The acquisition of Soleno and VYKAT XR was framed as a strategic fit that immediately accreted to non-GAAP earnings while extending the company's rare disease and endocrinology footprint.

Operational strength and disciplined capital deployment have provided the financial flexibility to invest in a pipeline that management describes as one of the industry's strongest mid-to-late stage portfolios.

The company emphasized its leadership in the VMAT2 category, noting that INGREZZA continues to outgrow the broader market despite competitive dynamics.

Management expects sequential quarterly growth for VYKAT XR exiting 2026 as the company integrates Soleno's operations and moves past the initial launch bolus of patient discontinuations.

Multiple Phase 3 clinical catalysts are scheduled for 2027, including data readouts for osavampator in major depressive disorder and dereclidine in schizophrenia.

The company anticipates maintaining strong Medicare access for INGREZZA through 2027 and 2028, though specific pricing impacts from the IRA implementation in 2029 remain under evaluation.

Strategic R&D focus is shifting toward a 'best-in-class' muscarinic franchise, with four distinct programs targeting schizophrenia, bipolar mania, and Alzheimer's disease.

Future SG&A investment levels will be contingent on Phase 3 readouts, particularly for osavampator, which would require a significant primary care sales force expansion if successful.

The $2.9 billion Soleno acquisition was financed entirely with cash on hand, leaving the company with $500 million in cash and no debt at quarter-end.

GAAP results included $130 million in acquisition-related costs and $20 million in non-cash purchase accounting amortization for the second quarter.

Management acknowledged a 'noisy' integration period for VYKAT XR, noting that discontinuation rates are expected to settle into a standard orphan medicine range of 25% to 30%.

The company flagged potential EPS variability in the late 2020s due to episodic investments required for large-market launches and the sunsetting of current Phase 3 trials.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management explained that current flat sequential sales were due to a bolus of discontinuations from the initial 2025 launch, which they expect to clear by Q3.

They reaffirmed confidence in VYKAT XR becoming a third blockbuster, citing steady new patient starts and a durable IP estate extending into the mid-2040s.

Management distinguished dereclidine as a selective M4 orthosteric agonist that does not require an 'add-back' antagonist to manage side effects, unlike competitors.

They emphasized that while efficacy gets products in the door, dereclidine will compete on safety, tolerability, and ease of administration (once-daily, no titration).

The prescriber base has nearly tripled year-over-year, though most physicians currently only have one or two patients on therapy due to the 'inch deep, mile wide' nature of the CAH market.

Management noted that 70% of patients in long-term studies achieved physiologic steroid doses, which they believe sets a high bar for future competitors.

Neurocrine is prioritizing its CRF2 agonist for obesity, targeting both weight loss and muscle mass preservation, with a signal-seeking readout expected next year.

The company views obesity as a way to diversify risk, utilizing objective biomarkers in early phases to balance the longer-cycle neuropsychiatry programs.